Comparing the Effectiveness of Bromfenac 0.09%, Nepafenac 0.3%, and Diclofenac 0.1% Eye Drops to Prevent Macular Oedema After Cataract Surgery

What this Trial Is About

Researchers are studying which of three eye drop medicationsbromfenac 0.09%, nepafenac 0.3%, and diclofenac 0.1%is more effective in preventing and treating cystoid macular oedema following cataract surgery. The study aims to find out which drug better prevents this condition and to compare the medical problems participants might have when using different drugs. Participants will be randomly assigned to use one of these drugs before and after their cataract surgery. Participants will use eye drops in their operated eye for up to 26 days, starting four days before surgery and continuing for 21 days after. The bromfenac group applies drops twice daily, the nepafenac group once daily, and the diclofenac group four times daily. This dosing schedule is followed throughout the treatment period to assess and compare the drugs effects. During the study, participants will visit the clinic for exams on the first day, one week, three weeks, and six weeks after surgery. Assessments include retina examination using optical coherence tomography OCT, vision tests, and questionnaires about their quality of life. Researchers will track the presence of macular oedema over six weeks and monitor changes in vision-related quality of life. The total participation lasts about six weeks after surgery with regular follow-up visits.

Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery